renal carcinoma
Conditions
Interventions
Case series:combined immunotherapy by RCAR plus PD-1 antibody
Sponsors
He'nan Cancer Hospital
Eligibility
Sex/Gender
All
Age
18 Years to 80 Years
Inclusion criteria
Inclusion criteria: 1. signing the informed consent voluntarily; 2. aged 18 to 80 years old; 3. diagnosed with renal cell carcinoma by pathology, progressing or intolerant to previously targeted therapy; 4. at one measurable lesion by RECIST 1.1 version; 5. ECOG=12 weeks; 7. sufficient organ function.
Exclusion criteria
Exclusion criteria: 1. receiving immunosuppressive or glucocorticoid therapy; 2. wounds caused by severe infections difficult to heal and suppurative inflammation difficult to control 3. Organic heart disease, cardiac insufficiency, cardiac conduction block above II, myocardial infarction occurred within 3 months; 4. Lung dysfunction caused by interstitial lung disease, lung ventilation reserve is lower than 80% of the expected value; 5. Participated in other clinical studies in the past month; 6. Severe hypersensitivity reactions have occurred after the application of other monoclonal antibody drugs; 7. previously received PD-1 or PD-L1 antibody treatment; 8. Active brain metastasis; 9. Uncontrolled chest, peritoneal effusion, pericardial effusion requiring repeated drainage; 10. Have received live vaccine or attenuated vaccination within 28 days before enrollment; 11. Major surgery was performed within 28 days prior to enrollment; 12. Conducted a solid organ transplant; 13. Pregnant lactating women; 14. With previous mental illness; 15. With history of other malignancy; 16. Other investigators believe that it is not appropriate to participate in the study (HIV infection, intravenous drug addicts, etc.), or other conditions that affect the analysis of the results of this clinical study.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| response rate;progression-free survival; | — |
Secondary
| Measure | Time frame |
|---|---|
| survival time; | — |
Countries
China
Contacts
Public ContactZhao Lingdi
He'nan Cancer Hospital
Outcome results
None listed